Phase II trial of paclitaxel/cisplatin followed by surgery and adjuvant radiation therapy and 5-fluorouracil/leucovorin for gastric cancer (ECOG E7296)

Gastrointestinal Cancer Research

Volumn 5, Issue 6, 2013, Pages 191-197

  Bapsi Chakravarthy, A ^a   Catalano, Paul J ^b   Mondschein, Joshua K ^a   Rosenthal, David I ^c   Haller, Daniel G ^d   Whittington, Richard ^d   Spitz, Francis R ^d   Wagner, Henry ^e   Sigurdson, Elin R ^f   Tschetter, Loren K ^g   Bayer, Gerald K ^h   Mulcahy, Mary F ⁱ   Benson, Al B ⁱ  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e PENN STATE CANCER INSTITUTE   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g Sanford Medical Center   (United States)

^h St Vincent Hospital Green Bay   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; PACLITAXEL;

ADJUVANT CHEMORADIOTHERAPY; ADVERSE OUTCOME; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CATHETER INFECTION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONFUSION; CONSCIOUSNESS DISORDER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FAINTNESS; FEBRILE NEUTROPENIA; FEMALE; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INDUCTION CHEMOTHERAPY; LEUKOPENIA; LOWER ESOPHAGUS SPHINCTER; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE PERIOD; RISK ASSESSMENT; SIDE EFFECT; STOMACH CANCER; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

EID: 84873697695     PISSN: 19347820     EISSN: 19347987     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Blot WJ, Devesa SS, Kneller RW, et al: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265:1287-1289, 1991
2. Songun I, Putter H, Kranenbarg EM, et al: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 11:439-449, 2010
3. Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725-730, 2001
4. Ajani JA, Winter K, Okawara GS, et al: Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol 24:3953-3958, 2006
5. Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9:1692-1703, 1991
6. Ilson DH, Ajani J, Bhalla K, et al: Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16:1826-1834, 1998
7. American Joint Committee on Cancer Staging Manual (3rd ed). Philadelphia: Lippincott, 1988
8. Hermanek P, Wittekind C: Residual tumor (R) classification and prognosis. Semin Surg Oncol 10:12-20, 1994
9. National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 2.0, 1999. Available at: http://ctep.cancer. gov/reporting/ctc.html. Accessed November 2, 2012
10. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
11. Siewert JR, Stein HJ: Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85:1457-1459, 1998
12. Lauren P: The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histo-clinical classification. Acta Pathologica et Microbiologica Scandinavica 64:31-49, 1965
13. Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20, 2006
14. Snyder RA, Castaldo ET, Bailey CE, et al: Survival benefit of adjuvant radiation therapy for gastric cancer following gastrectomy and extended lymphadenectomy. Int J Surg Oncol 2012:11-307670, 2012
15. Lee J, Lim do H, Kim S, et al: Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 30:268-273, 2012
16. van Hagen P, Hulshof MC, van Lanschot JJ, et al: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074-2084, 2012
17. Fuchs CS, Tepper, JE, Niedzwiecki D, et al: Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: intergroup trial CALGB 80101. J Clin Oncol 29:2074-4003, 2011
18. Bang YJ, Kim YW, Yang HK, et al: Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379:315-321, 2012
19. Sakuramoto S, Sasako M, Yamaguchi T, et al: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810-1820, 2007
20. Dikken JL, van Sandick JW, Maurits Swellengrebel HA, et al: Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer 11:329, 2011